Radionetics Oncology

Radionetics Oncology is a pharmaceutical company focused on the discovery and development of novel precision radiopharmaceuticals for the treatment of various oncology indications. The company leverages Crinetics Pharmaceuticals' core non-peptide, small molecule platform to deliver therapeutic radioisotopes to multiple cancers by selectively binding to peptide receptors that are selectively expressed on these tumors. This non-peptide technology addresses many of the significant challenges currently faced by peptide and protein-targeted radiotherapies, particularly in optimizing drug properties and manufacturing. The company is rapidly advancing a pipeline of drug candidates to treat a wide range of cancers and is collaborating with Crinetics Pharmaceuticals on additional drug discovery efforts to identify candidates targeting additional receptor sites.